Intuitive Surgical (NSDQ:ISRG) said today that the FDA cleared its new single-site instruments and accessories for the next-generation da Vinci Xi robot-assisted surgery device.
The tools allow surgeons to perform cholecystectomies, benign hysterectomies and salpingo-oophorectomies via a single incision in the umbilicus, Sunnyvale, Calif.-based Intuitive said.
“The da Vinci Xi was designed to seamlessly integrate advanced and future technologies and we are extremely pleased to further expand our line of product offerings with the clearance of single-site instruments and accessories,” EVP Sal Brogna said in prepared remarks. “Single-site technology adds great versatility to the da Vinci Xi by enabling both single port and multi-port surgery on a single system.”
The da Vinci Xi, the 4th generation of Intuitive’s platform, 1st won FDA clearance in April 2014. Earlier this week, the company won the federal safety watchdog’s clearance for the EndoWrist 30 stapler.